Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Therapy with Systemic Therapy for Oligoprogressive NSCLC
NCT07076693Phase 3Active, not recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2025
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Objective Response Rate up to 7 weeks and Progression-free survival up to 3 years. Started Jun 2025; status: active, not recruiting.
Beyond the preview
Go deeper on NCT07076693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076693.